



*Press release*

*Stockholm, Oct 26, 2010*

## Interim Report – January to Sept 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the nine-month period ended September 30, 2010.

### Financial Highlights

- Revenue for the first nine months of 2010 was SEK 20.3 (19.0) million
- Net loss for the period amounted to SEK -15.8 (-19.0) million
- Earnings per share was SEK -0.19 (-0.42)
- Cash flow from current operations was SEK -18.5 (-31.4) million
- SEK 27.6m raised in additional financing of which 23.8m in cash

### Key Corporate Highlights

- Shortly after the close of the reporting period Affibody and Amylin entered into a license agreement regarding the Albumod™ platform.
- During the period Affibody signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.
- The Swedish Governmental Agency for Innovation Systems (VINNOVA) has awarded Affibody a grant from their Innovations for Future Health program. The grant will enable Affibody to take the Albumod™ technology to human clinical testing.
- The Swedish MPA (Läkemedelsverket) has approved an exploratory clinical study in breast cancer patients at Uppsala University Hospital, Uppsala, Sweden with Affibody’s lead molecular imaging agent, ABY-025.
- The share issue directed to existing shareholders raised SEK 27.6 million gross to the company after which the total number of shares increased to 102 858 403.

David Bejker CEO, said: *“We are pleased to announce our agreement with Amylin. It is encouraging that our focused research and business development activities have started to pay off. Our platforms continue to generate significant interest both from industry and academia.”*

### Enquiries

David Bejker, CEO

**+46 706 454 948**

Johan Stuart CFO

**+46 706 644 096**

## **About Affibody**

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: [www.affibody.com](http://www.affibody.com)



Lindhagensgatan 133, SE-112 51 Stockholm, Sweden.  
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, [www.affibody.com](http://www.affibody.com)